You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)擬折讓11.5%配股總籌10.39億港元,七成用於創新藥研發
格隆匯 06-13 07:38

格隆匯6月13日丨君實生物(01877.HK)發佈公吿,2025年6月12日,公司與獨家配售代理(即瑞銀集團)訂立配售協議,據此,公司同意委任獨家配售代理,以及獨家配售代理同意作為公司的代理盡最大努力促使至少六名承配人按配售價格每股H股25.35港元以及根據配售協議所載條款並在其條件規限下認購配售股份(即公司擬配發及發行的不超過4100萬股新H股)。

配售價格較6月12日(即最後交易日)在香港聯交所所報收市價每股H股28.65港元折讓約11.52%。4100萬股配售股份約佔(i)公司於本公吿日期全部已發行H股的18.70%及全部已發行股份的4.16%,及(ii)經配發及發行配售股份而有所擴大的全部已發行H股的15.75%及全部已發行股份的3.99%。配售股份將根據一般授權配發及發行,且毋須任何股東批准。

假設所有配售股份均獲配售,配售事項合計所得款項總額預期約為10.39億港元以及配售事項合計所得款項淨額預期約為10.26億港元。集團擬將配售所得款項淨額的70%用於創新藥研發,包括PD-1/VEGF雙特異性抗體(代號JS207)、EGFR/HER3雙特異性抗體偶聯藥物(代號JS212)、PD-1/IL-2雙功能性抗體融合蛋白(代號JS213)及其他在研管線的開發;並將配售事項所得款項淨額的30%用於補充營運資金等一般企業用途。公司將向上市委員會申請批准配售股份於香港聯交所上市及買賣,以及就配售事項遵守中國證監會規定並完成中國證監會備案。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account